Stock SLDB SOLID BIOSCIENCES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Solid Biosciences Inc.

Equities

SLDB

US83422E2046

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
9.26 USD -7.31% Intraday chart for Solid Biosciences Inc. -13.13% +50.81%
Apr. 01 Solid Biosciences' SGT-003 Receives US FDA's Rare Pediatric Disease Label MT
Apr. 01 Solid Biosciences Gets FDA Rare-Pediatric Designation for SGT-003 in Duchenne DJ

Business Summary

Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. The Company also has two cardiac pipeline gene transfer programs, SGT-601 for TNNT2 DCM and SGT-701 for RBM20 DCM, that are both in early preclinical development. It also has a neuromuscular gene transfer program for the treatment of Friedreich's ataxia. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including novel capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.

Number of employees: 88

Managers

Managers TitleAgeSince
Annie Ganot FOU
 Founder - 13-02-28
Ilan Ganot FOU
 Founder 50 13-02-28
Alexander Cumbo CEO
 Chief Executive Officer 53 22-09-28
Kevin Tan DFI
 Director of Finance/CFO 46 23-01-08
Gabriel Brooks CTO
 Chief Tech/Sci/R&D Officer - 23-10-01
Jenny Marlowe CTO
 Chief Tech/Sci/R&D Officer 47 22-12-31
Paul Herzich CTO
 Chief Tech/Sci/R&D Officer 46 22-11-30
TY Howton COO
 Chief Operating Officer 52 22-11-30
Shuli Kulak PRN
 Corporate Officer/Principal - -
Jessie Hanrahan LAW
 General Counsel 47 22-11-30

Members of the board

Members of the board TitleAgeSince
Ian Smith CHM
 Chairman 58 20-04-14
Martin Freed BRD
 Director/Board Member 63 18-06-25
Raj Shah BRD
 Director/Board Member 46 17-02-28
Adam Stone BRD
 Director/Board Member 44 15-10-31
Sukumar Nagendran BRD
 Director/Board Member 58 18-09-11
Alexander Cumbo CEO
 Chief Executive Officer 53 22-09-28
Ilan Ganot FOU
 Founder 50 13-02-28
Lynne Sullivan BRD
 Director/Board Member 58 15-10-31
Georgia Keresty BRD
 Director/Board Member 62 21-03-01
Clare Khan BRD
 Director/Board Member 72 21-03-01

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 37,756,877 30,552,823 ( 80.92 %) 0 80.92 %

Shareholders

NameEquities%Valuation
Perceptive Advisors LLC
18.34 %
6,925,028 18.34 % 92 M $
RA Capital Management LP
11.05 %
4,173,834 11.05 % 56 M $
Bain Capital Life Sciences LP
10.69 %
4,034,582 10.69 % 54 M $
Perceptive Advisors LLC
9.259 %
3,495,933 9.259 % 47 M $
RA Capital Management LP
9.075 %
3,426,286 9.075 % 46 M $
Invus Public Equities Advisors LLC
7.197 %
2,717,538 7.197 % 36 M $
Adage Capital Management LP
7.184 %
2,712,478 7.184 % 36 M $
Deerfield Management Co. LP (Private Equity)
5.987 %
2,260,398 5.987 % 30 M $
Camber Capital Management LP
3.757 %
1,418,439 3.757 % 19 M $
Finepoint Capital LP
2.546 %
961,251 2.546 % 13 M $

Company contact information

Solid Biosciences, Inc.

500 Rutherford Avenue 3rd floor

02129, Charlestown

+

http://www.solidbio.com
address Solid Biosciences Inc.(SLDB)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
9.26 USD
Average target price
17.78 USD
Spread / Average Target
+91.98%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
SOLID BIOSCIENCES INC. Stock Solid Biosciences Inc.
+50.81% 377M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.30% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.79% 96.84B
ARGENX SE Stock argenx SE
-0.44% 21.48B
BIONTECH SE Stock BioNTech SE
-18.35% 20.82B
GENMAB A/S Stock Genmab A/S
-7.45% 18.6B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.31% 16.81B
BEIGENE, LTD. Stock BeiGene, Ltd.
-26.84% 13.78B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.59% 13.4B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+20.86% 11.06B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. SLDB Stock
  4. Company Solid Biosciences Inc.